In 2025, the NHS dispensed roughly 85 million antidepressant prescriptions in England alone, a record high and a near-doubling over the past decade. Yet during that same period, the average wait for a first talking-therapy appointment through the NHS Improving Access to Psychological Therapies (IAPT) programme stretched past 18 weeks in many areas. The gap between medication supply and therapy access has become a defining feature of UK mental healthcare—a system that, by default, steers patients toward pills while they wait for something that may never arrive.

The Pills-Without-Talk Trade-Off

Clinical guidelines from the National Institute for Health and Care Excellence (NICE) recommend that for mild to moderate depression, talking therapies such as cognitive behavioural therapy (CBT) should be offered as a first-line treatment. Antidepressants are advised for moderate to severe depression, ideally in combination with therapy. In practice, however, the two rarely arrive together.

A 2024 survey by the Royal College of General Practitioners found that over 60% of GPs had prescribed an antidepressant in the previous month specifically because therapy slots were unavailable. “I’m not happy about it,” one GP told the researchers. “But if someone is in distress and the wait is six months, I can’t send them home with nothing.” The result is a default medication-first pathway that many clinicians consider suboptimal.

The trade-off is not merely about patient preference. Antidepressants carry side effects—nausea, weight gain, sexual dysfunction—that lead roughly one in three patients to discontinue within six months. Therapy, by contrast, has no pharmacological side effects and equips patients with coping skills that may reduce relapse risk. Yet the system’s incentives favour the cheaper, scalable option: a six-month supply of generic sertraline costs the NHS roughly £20, whereas a course of CBT runs several hundred pounds per patient.

This cost calculus, however, ignores downstream consequences. Patients who start antidepressants without therapy are more likely to remain on medication long-term, and the proportion of people taking antidepressants for more than two years has risen steadily. Some experts argue that the true cost of the pills-without-talk model is measured not in pounds but in lost opportunities for recovery.

Consider the case of James, a 28-year-old software developer in Leeds. He was prescribed citalopram for anxiety in 2023 after a six-month wait for therapy. The medication helped initially, but after a year he felt emotionally flat and gained roughly 12 kilograms. “I didn’t feel like myself anymore,” he says. When he finally started CBT, his therapist noted that his avoidance behaviours had become entrenched, making treatment more difficult. James’s story highlights a pattern: delayed therapy can allow maladaptive coping strategies to solidify, potentially reducing the effectiveness of later psychological intervention.

Another dimension of the trade-off involves children and adolescents. Young people referred to Child and Adolescent Mental Health Services (CAMHS) for therapy often face even longer waits—sometimes exceeding 12 months in parts of England. During that time, GPs may prescribe antidepressants off-label for under-18s, despite limited evidence for their efficacy in this age group. A 2024 study in The Lancet Psychiatry found that antidepressant prescribing for adolescents in England rose by roughly 35% between 2020 and 2024, while access to CAMHS therapy remained flat. The implications are concerning: young brains are still developing, and the long-term effects of early antidepressant exposure are not fully understood.

A Patient's Story: Stuck on a Waiting List

Sarah M., a 34-year-old teacher in Manchester, first sought help for depression in January 2025. Her GP diagnosed moderate depression and referred her for CBT through IAPT. The earliest appointment she was offered: late June 2025, roughly 24 weeks away. “I sat in my car and cried,” she recalls. “I knew I couldn’t wait that long.”

Her GP prescribed sertraline, starting at 50 mg daily, as a bridge. The medication helped with sleep and appetite within a few weeks, but Sarah says she felt “numb” and struggled to engage with the underlying thoughts that had driven her to seek help. When her CBT sessions finally began, she had already been on sertraline for five months. “The therapist asked what I wanted to work on, and I realised I’d forgotten why I’d come,” she says.

Sarah’s experience is not unusual. A 2025 survey by the charity Mind found that roughly 40% of people referred for NHS therapy waited more than six months for a first appointment. During that time, nearly three-quarters were prescribed medication, often without a clear plan for when—or if—therapy would follow. Many patients, like Sarah, end up continuing medication alone, unsure whether the therapy they waited for will still be relevant.

“I’m still on sertraline,” Sarah says. “I don’t know if I’d need it if I’d had therapy sooner. But now I’m scared to stop.” Her story illustrates a system that treats medication as a stopgap, yet fails to ensure the intended destination is ever reached.

Sarah’s case also raises a question about informed consent. When she was prescribed sertraline, she says her GP did not discuss potential long-term use or a tapering plan. A 2024 review by the All-Party Parliamentary Group for Prescribed Drug Dependence found that many patients are not told about withdrawal symptoms, which can include dizziness, nausea, and emotional instability. This lack of information can make patients feel trapped on medication, unsure how to stop even if they want to.

Why Therapy Wait Times Keep Growing

The roots of the wait-time crisis are structural. IAPT was launched in 2008 with ambitious targets: 90% of patients seen within 18 weeks, and 50% moving to recovery. For a few years, the programme made progress. But funding has been frozen in real terms since 2021, while demand has risen by roughly 30% since the pandemic. The result is a system stretched thin.

Workforce shortages are a key bottleneck. Health Education England estimates that the IAPT workforce needs an additional 2,000 therapists to meet current demand, but training pipelines remain slow. The typical route—a postgraduate diploma in CBT—takes at least one year, and many graduates are lured to private practice or higher-paying NHS roles in other specialties. Turnover among IAPT therapists hovers around 20% annually, according to a 2024 parliamentary report.

The COVID-19 pandemic left a lasting backlog. During lockdowns, referrals to IAPT dropped sharply as people avoided healthcare settings, only to surge later. Many services are still working through that backlog while facing ongoing demand from new patients. In some areas, commissioners have prioritised “high-volume, low-intensity” interventions—such as online guided self-help—to meet access targets, but these may not suit patients with more complex needs.

Commissioning models also play a role. IAPT services are often paid per contact, creating an incentive to see more patients briefly rather than provide longer, more intensive therapy. Critics argue this focus on throughput undermines quality and leaves patients cycling through short interventions without lasting improvement. “We’re measuring activity, not outcomes,” one clinical psychologist told a 2023 inquiry.

A further complication is the postcode lottery of provision. In some areas of England, IAPT services are well-staffed and patients can be seen within four to six weeks; in others, waits routinely exceed six months. A 2025 analysis by the Nuffield Trust found that the variation is not explained by local need alone, but by historical funding patterns and the availability of training placements. This inequity means that where you live can determine whether you receive timely therapy or a prescription pad.

What the Evidence Says About Medication vs. Therapy

Decades of research support both antidepressants and talking therapies, but the evidence for their relative merits is nuanced. A 2021 meta-analysis in The Lancet found that antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), show moderate efficacy for moderate to severe depression compared with placebo. The number needed to treat (NNT) for a response is roughly 7, meaning one in seven patients benefits beyond placebo. That is a real effect, but far from universal.

CBT, the most studied talking therapy, has shown comparable efficacy to antidepressants for moderate depression in head-to-head trials, with the advantage of no pharmacological side effects. A 2023 Cochrane review concluded that CBT reduces depressive symptoms with a moderate effect size (standardised mean difference around 0.5) and that gains are often maintained after treatment ends. Long-term follow-up studies suggest that CBT may reduce relapse rates by 30–50% compared with medication alone.

Combination therapy—medication plus CBT—consistently yields the highest remission rates. A landmark 2021 study in JAMA Psychiatry found that patients who received both had a 60% higher chance of remission at 12 months than those on medication alone. Yet combination therapy remains the exception in NHS practice, largely because the therapy component is unavailable.

NICE guidelines recommend talking therapies as first-line for mild depression, and antidepressants only for moderate or severe cases. In practice, however, many patients with mild depression receive medication because therapy waits are too long. “We’ve inverted the guidelines,” says Dr. Emma Robinson, a GP in Bristol. “We’re using pills for people who should be offered therapy, because that’s what we can deliver today.”

It is worth noting that not all patients prefer therapy. Some find the structured nature of CBT demanding, especially during acute episodes when motivation is low. Others have had negative experiences with therapy or cannot commit to weekly sessions due to work or caring responsibilities. For these individuals, medication may be a more practical first step. The problem is not that medication is prescribed, but that it is prescribed without the option of therapy being meaningfully available.

Moreover, the evidence base for therapy is not without limitations. Many CBT trials have relatively small sample sizes and short follow-up periods, and the outcomes are often measured with self-report scales that may not capture real-world functioning. A 2024 meta-analysis in BMJ Open found that the effect of CBT on depression may be inflated by publication bias, with smaller negative trials going unpublished. Still, the overall consensus remains that therapy is effective, and for many patients, it is the preferred treatment.

How Other High-Income Systems Compare

The UK is not alone in struggling with therapy access, but some peer countries have managed better. Australia’s Better Access initiative, launched in 2006, provides Medicare rebates for up to 10 individual therapy sessions per year (with additional sessions for complex cases). The scheme has expanded access significantly: roughly 1.5 million Australians use it annually, and wait times for private therapists are typically under four weeks. However, out-of-pocket costs remain a barrier for low-income patients.

Germany’s statutory health insurance system covers psychotherapy extensively, with 25–50 sessions per course depending on diagnosis. Wait times vary by region but average around 12 weeks, partly because the system mandates a fixed number of therapy slots per insurer. A 2023 analysis found that Germany spends roughly 1.5 times more per capita on outpatient psychotherapy than the UK.

Canada and the United States face different challenges. In Canada, provincial health plans cover physician-provided therapy (usually psychiatrists) but not most psychologists or counsellors, leading to waits of six months or more for publicly funded care. The US, despite the Mental Health Parity and Addiction Equity Act, sees high deductibles and limited provider networks; a 2024 survey found that 40% of Americans with private insurance reported difficulty finding an in-network therapist with openings.

Only the Netherlands consistently meets the EU benchmark of a maximum four-week wait for outpatient mental health care, achieved through a combination of mandatory insurance coverage for therapy, a well-distributed workforce, and integrated primary care. The Dutch model, however, is expensive and may not be directly replicable in the UK’s budget-constrained NHS.

Each of these systems involves trade-offs. Australia’s model relies on private providers, which can create inequities. Germany’s system is heavily regulated, which may limit patient choice. The Netherlands invests heavily in mental health, but its overall healthcare spending is among the highest in Europe. The UK’s challenge is to find a model that balances access, quality, and cost—a difficult equation when demand is rising faster than funding.

What Clinicians and Campaigners Are Calling For

Patient groups and professional bodies have coalesced around a set of demands. First, ring-fenced funding for talking therapies, separate from broader mental health trust budgets, to prevent diversion to crisis services. The Royal College of Psychiatrists has called for an additional £500 million annually to expand IAPT capacity.

Second, workforce expansion through accelerated training routes, such as “apprenticeship-style” programmes that allow existing healthcare workers—nurses, social workers, occupational therapists—to upskill in CBT or other evidence-based therapies. Pilot schemes in London and Manchester have shown that such routes can produce competent therapists in 12–18 months, compared with the standard two-year postgraduate route.

Third, integration of digital CBT tools to reduce face-to-face demand. NHS-approved platforms like SilverCloud and Ieso offer structured therapy programmes with some human support, and early evidence suggests they are effective for mild to moderate depression. However, uptake remains low, and critics warn that digital tools should complement, not replace, in-person therapy for those who need it.

Finally, campaigners are pushing for a national target: a maximum six-week wait for talking therapies by 2030, backed by a statutory duty on commissioners to meet it. “Patients deserve a choice,” says Mark Winstanley, chief executive of the charity Rethink Mental Illness. “Right now, the choice is an illusion. You get pills or nothing.”

Some clinicians also advocate for a shift in how depression is conceptualised. Rather than viewing medication and therapy as competing options, they argue for a stepped-care model that matches treatment intensity to need. In this model, patients with mild symptoms might start with guided self-help, those with moderate symptoms could receive brief therapy or medication, and those with severe or complex conditions would be offered combination therapy. The challenge is implementing such a model when the lower steps are already overwhelmed.

Small Steps Patients Can Take Now

While systemic change is slow, there are actions patients can take in the interim. First, ask your GP about low-intensity guided self-help programmes, often available through IAPT without a long wait. These typically involve a workbook or online modules with brief telephone support from a trained practitioner. For some, this is enough to manage symptoms until full therapy begins.

Second, explore local charities and community organisations that offer sliding-scale therapy. Many areas have counselling services funded by local authorities or donations, with fees based on income. The British Association for Counselling and Psychotherapy (BACP) maintains a directory of accredited therapists offering reduced-cost sessions.

Third, consider NHS-approved digital therapy apps. SilverCloud and Ieso are available free through many GP practices and provide structured CBT programmes with optional therapist feedback. Evidence from a 2024 randomised trial showed that SilverCloud reduced PHQ-9 depression scores by an average of 4 points over eight weeks, comparable to face-to-face therapy.

Peer support groups, such as those run by Mind or the Depression Alliance, can also provide emotional support while you wait. While not a substitute for professional treatment, they can reduce isolation and help you track mood and symptoms—information that may be useful when you eventually see a therapist. Keep a simple log of your mood, sleep, and energy levels; this can help your clinician tailor treatment.

Finally, if you are already on medication, do not stop abruptly. Discuss any concerns with your GP, who can help you weigh the risks and benefits. The goal is not to choose between pills and talk, but to find a path that works for you—even if the system makes that path harder to follow than it should be.

This article is for informational purposes only and does not constitute personalised medical advice. If you are experiencing a mental health crisis, please contact your GP or call 111 (NHS) or 999 in an emergency.